DANUBE研究比较了CTLA-4抑制剂tremelimumab和PD-L1抑制剂durvalumab的免疫治疗组合(IO-IO)与单独化疗或durvalumab单独治疗。 在ITT组中,IO-IO联合疗法与化疗的改善OS的共同主要终点在PT-L1阳性人群中没有达到,durvalumab单药治疗与化疗的OS也没有改善 [4] 。 三项研究结果均未能改变吉西他滨联合顺铂的化疗方案在...
参考文献 [1]Do-Youn Oh, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer ...
参考文献: [1] Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D...
leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J Clin Oncol ...
参考资料: 1. Do-Youn Oh, et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. 2023 ESMO ASIA ...
Pts with BTC were randomized 1:1 to D (1500 mg once every 3 weeks [Q3W]) or PBO, + G (1000 mg/m2) and C (25 mg/m2) on Days 1 and 8, Q3W, for up to 8 cycles, followed by D (1500 mg Q4W) or PBO monotherapy until disease progression or unacceptable toxicity. Hazard ...
Regardless of geographic location, the results favored the addition of durvalumab compared to placebo. What is great to see is that over 90% of patients were able to complete their FLOT therapy before surgery, and 65% of patients were able to complete adjuvant FLOT, so all four cycles. That...
参考文献:T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). 编译:天津市肿瘤医院 王成蒙 05 【4088】第四代嵌合抗原受体T细胞靶向磷脂酰肌醇聚糖-3治疗晚期肝癌的...
Purpose/Objective(s): Platinum-based chemotherapy with pemetrexed is an appropriate first line treatment option for unresectable malignant pleural mesothelioma (MPM) The DREAM and PrE0505 Phase II trials combined durvalumab (PD-L1 inhi... P Forde,H Kindler,M Zauderer,... - International Journal ...
在当地时间18日的口头报告专场,美国纪念斯隆-凯特琳癌症中心(Memorial Sloan Kettering Cancer Center)Yelena Y. Janjigian教授汇报了MATTERHORN研究中FLOT联合或不联合度伐利尤单抗治疗GC/GEJC(胃/胃食管结合部癌)的亚组pCR分析最新结果(LBA246)。在《肿瘤瞭望》现场采访中,Yelena Y. Janjigian教授分享了MATTERHORN...